Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05211284 · ClinicalTrials.gov registry record · Phase 2
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US
A Phase 2 study, sponsored by Zydus Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT05211284: Clinical Trial Phase 2 study, sponsored by Zydus Therapeutics.
NCT05211284 is a Phase 2 study that was terminated before completion, run by Zydus Therapeutics. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05211284, a Phase 2 study, was terminated before completion, sponsored by Zydus Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US
Primary Outcome
Change from baseline in hepatic fat content
Interventions
- DRUG Placebo
- DRUG Saroglitazar Magnesium 4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2023-10-02 |
| Phase | Phase 2 |
Why NCT05211284 stopped before completion
NCT05211284 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05211284 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05211284 about?
NCT05211284 is a clinical study titled "Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US". Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US
What is the current status of trial NCT05211284?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2022-12-08. Estimated completion is 2023-10-02.
What interventions are being tested in trial NCT05211284?
The interventions under investigation include: Placebo (DRUG), Saroglitazar Magnesium 4 mg (DRUG).
Who is sponsoring clinical trial NCT05211284?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05211284's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI